Cartesian Therapeutics (RNAC) FCF Margin (2015 - 2026)
Cartesian Therapeutics (RNAC) reported FCF Margin of 28453.85% for Q1 2026, down 2630448.0% year-over-year from N/an in Q1 2025, and down 2366.43% quarter-over-quarter from 1255.45% in Q4 2025.
Cartesian Therapeutics (RNAC) FCF Margin (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has 12 years of FCF Margin data on file, last reported at 28453.85% in Q1 2026.
- FCF Margin for Q1 2026 came in at 28453.85%, down 2630448.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 8472.39% (up 859377.0% YoY), and the FY2025 annual result was 19848.75%, down 1976314.0% from the prior year.
- FCF Margin slipped to 28453.85% in Q1 2026 per RNAC's latest filing, from 1255.45% in the prior quarter.
- Over five years, FCF Margin peaked at 1935.92% in Q3 2024 and troughed at 28453.85% in Q1 2026.
- A 5-year average of 2028.79% and a median of 105.65% in 2022 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2024 and 2026: FCF Margin surged 207541 bps in 2024, then slumped 2630448 bps in 2026.
- A 5-year view of FCF Margin shows it stood at 71.81% in 2022, then slumped by 293 bps to 282.47% in 2023, then surged by 295 bps to 551.68% in 2024, then soared by 128 bps to 1255.45% in 2025, then sank by 2366 bps to 28453.85% in 2026.
- Business Quant data shows RNAC's FCF Margin at 28453.85% in Q1 2026, 1255.45% in Q4 2025, and 4396.9% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Cartesian Therapeutics | 261.84 Mn | 261.84 Mn | - | -28,453.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28,453.85% |
| Dec 31, 2025 | 1,255.45% |
| Sep 30, 2025 | -4,396.90% |
| Mar 31, 2025 | -2,149.36% |
| Dec 31, 2024 | 551.68% |
| Sep 30, 2024 | 1,935.92% |
| Jun 30, 2024 | -50.00% |
| Mar 31, 2024 | -272.55% |
| Dec 31, 2023 | -282.47% |
| Sep 30, 2023 | -139.49% |
| Jun 30, 2023 | -188.74% |
| Mar 31, 2023 | -149.80% |
| Dec 31, 2022 | -71.81% |
| Sep 30, 2022 | 18.91% |
| Jun 30, 2022 | -32.42% |
| Mar 31, 2022 | -35.16% |
| Dec 31, 2021 | -105.78% |
| Sep 30, 2021 | -44.05% |
| Jun 30, 2021 | -30.62% |
| Mar 31, 2021 | -110.03% |